Chief Legal Officer

Chief Financial Officer

President

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Institution	Shares	Value	Change
FMR	51,859,891	$3.6B	INCREASED
Vanguard	41,976,522	$2.9B	INCREASED
BlackRock	30,599,409	$2.1B	INCREASED
Capital Group	22,276,996	$1.6B	INCREASED
Baillie Gifford	18,206,778	$1.3B	DECREASED

Insider	Type	Shares	Value	Date
Shannon Thyme Klinger (Chief Legal Officer)	TAX-W	5,704	$849K	2026-09-04
Shannon Thyme Klinger (Chief Legal Officer)	EXERCISE	11,797		2026-09-04
James M Mock (Chief Financial Officer)	TAX-W	5,704	$849K	2026-09-04
James M Mock (Chief Financial Officer)	EXERCISE	11,797		2026-09-04
Stephen Hoge (President)	TAX-W	4,489	$630K	2026-09-01

Member	Type	Amount	Date
Maria Elvira Salazar (Republican)	SALE	$1,001 - $15,000	2026-08-19
Maria Elvira Salazar (Republican)	PURCHASE	$1,001 - $15,000	2026-08-19

Moderna, Inc. Common Stock (MRNA) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades